Crinetics Pharmaceuticals announced that it has dosed the first patient in its BALANCE‑CAH Phase 2/3 study of atumelnant, a once‑daily oral ACTH receptor antagonist, for classic congenital adrenal hyperplasia (CAH) in children and adolescents. The dosing took place on January 22, 2026 and marks the first clinical exposure of atumelnant in a pediatric population.
The BALANCE‑CAH trial is structured in three parts: an open‑label dose‑range Phase 2, a double‑blind Phase 3, and an open‑label extension. The design is intended to serve as a potential registrational study, with the Phase 3 portion expected to provide the data needed for a regulatory filing in the pediatric indication. The trial’s primary completion is projected for March 2030, giving the company a clear timeline to demonstrate safety, efficacy, and pharmacokinetics in a population that currently relies on supraphysiologic glucocorticoid doses with significant long‑term health risks.
Chief Endocrinologist Dr. Alan Krasner emphasized that the pediatric trial expands Crinetics’ pipeline beyond its approved acromegaly therapy, Palsonify, and positions atumelnant as a disease‑modifying treatment for CAH and potentially ACTH‑dependent Cushing’s syndrome. He noted that the orphan drug designation for classic CAH, granted by the FDA, provides a regulatory incentive and potential market exclusivity that could accelerate commercialization. The company’s recent launch of Palsonify, which achieved $5 million in Q4 2025 sales, demonstrates its ability to bring a small‑molecule endocrine therapy to market.
The initiation of the pediatric study increases near‑term R&D expenditures and may require additional capital, but it also expands the addressable market for atumelnant from adults to children and adolescents. Analysts have highlighted the positive Phase 2 TouCAHn results in adults, which showed significant reductions in androstenedione, as a key driver of prior optimism. The company’s public offering of 7.62 million shares at $45.95 per share, expected to raise approximately $350 million, provides the financial cushion needed to support the expanded development program. Market reaction to the announcement was muted, with the stock closing slightly lower on the day, reflecting investor caution about the increased costs and the long timeline to regulatory approval.
Looking ahead, Crinetics plans to complete the Phase 3 portion of BALANCE‑CAH by 2027, with data expected in 2028. Successful results could lead to a pediatric approval that would complement the adult indication and unlock a larger commercial opportunity. The company’s strategy to pursue orphan drug status, coupled with its proven small‑molecule platform, positions it to capture a significant share of the unmet need in pediatric endocrine disorders.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.